Lamisil fights fungal infections. In tablet form, it's used for fungus of the toenail or fingernail. The cream and the solution are used for other fungal infections such as athlete's foot, jock itch, and ringworm. The solution is also used to treat tinea versicolor, a fungal infection that produces brown, tan, or white spots on the trunk of the body. Lamisil does not produce instant results. You won't see the full effect of the tablets for several months, until a healthy new nail has grown out. The cream and solution also work gradually. It usually takes a week for results to appear, and improvement often continues for 2 to 6 weeks after treatment has stopped.


I recommend buying Lamisil (Terbinafine) from

- Discount Online Pharmacy All-Drugs-Pharmacy.com (It ships to USA only)

- Healways.com (This international pharmacy ships worldwide and offers great discounts)

- Xanax, Diazepam, Zolpidem and much more... International Pharmacy based in Switzerland. Worldwide shipping!

90% of online pharmacies are merely scammers like Mdzn.com, Cydrugs.com and more others. You can check the list of scam pharmacies here. I learned this from my own painful experience and therefore would like to defend all consumers from potential danger of been ripped off.
All-Drugs-Pharmacy.com offers pretty low prices (plus 20% discounts), high quality customer support, wide range of prescription medications, online consultations, FedEx shipping. At present it ships within USA only.

CLINICAL STUDIES

The efficacy of LAMISIL® (terbinafine hydrochloride tablets) Tablets in the treatment of onychomycosis is illustrated by the response of patients with toenail and/or fingernail infections who participated in three US/Canadian placebo-controlled clinical trials.
Results of the first toenail study, as assessed at week 48 (12 weeks of treatment with 36 weeks follow-up after completion of therapy), demonstrated mycological cure, defined as simultaneous occurrence of negative KOH plus negative culture, in 70% of patients. Fifty-nine percent (59%) of patients experienced effective treatment (mycological cure plus 0% nail involvement or >5mm of new unaffected nail growth); 38% of patients demonstrated mycological cure plus clinical cure (0% nail involvement).

In a second toenail study of dermatophytic onychomycosis, in which non-dermatophytes were also cultured, similar efficacy against the dermatophytes was demonstrated. The pathogenic role of the non-dermatophytes cultured in the presence of dermatophytic onychomycosis has not been established. The clinical significance of this association is unknown.
Results of the fingernail study, as assessed at week 24 (6 weeks of treatment with 18 weeks follow-up after completion of therapy), demonstrated mycological cure in 79% of patients, effective treatment in 75% of the patients, and mycological cure plus clinical cure in 59% of the patients.

The mean time to overall success was approximately 10 months for the first toenail study and 4 months for the fingernail study. In the first toenail study, for patients evaluated at least six months after achieving clinical cure and at least one year after completing LAMISIL® therapy, the clinical relapse rate was approximately 15%.

CONTRAINDICATIONS

LAMISIL® (terbinafine hydrochloride tablets) Tablets are contraindicated in individuals with hypersensitivity to terbinafine or to any other ingredients of the formulation.

WARNINGS

Rare cases of liver failure, some leading to death or liver transplant, have occurred with the use of LAMISIL® Tablets for the treatment of onychomycosis in individuals with and without pre-existing liver disease.
In the majority of liver cases reported in association with LAMISIL® use, the patients had serious underlying systemic conditions and an uncertain causal association with LAMISIL®. The severity of heptic events and/or their outcome may be worse in patients with active or chronic liver disease (see PRECAUTIONS). Treatment with LAMISIL® Tablets should be discontinued if biochemical or clinical evidence of liver injury develops.
There have been isolated reports of serious skin reactions (e.g., Stevens-Johnson Syndrome and toxic epidermal necrolysis). If progressive skin rash occurs, treatment with LAMISIL® should be discontinued.

In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. In vitro studies have also shown that terbinafine inhibits CYP2D6-mediated metabolism. This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants, ?-blockers, selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window.
In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin. Terbinafine decreases the clearance of caffeine by 19%. Terbinafine increases the clearance of cyclosporine by 15%. There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between LAMISIL® Tablets and these changes has not been established.
Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. Terbinafine clearance is unaffected by cyclosporine.
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.

Nursing Mothers After oral administration, terbinafine is present in breast milk of nursing mothers. The ratio of terbinafine in milk to plasma is 7:1. Treatment with LAMISIL® is not recommended in nursing mothers.

The safety and efficacy of LAMISIL® have not been established in pediatric patients.

Clinical experience regarding overdose with LAMISIL® (terbinafine hydrochloride tablets) Tablets is limited. Doses up to 5 grams (20 times the therapeutic daily dose) have been taken without inducing serious adverse reactions. The symptoms of overdose included nausea, vomiting, abdominal pain, dizziness, rash, frequent urination, and headache.